The New England journal of medicine
-
Clinical Trial Controlled Clinical Trial
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Deferiprone is an orally active iron-chelating agent that is being evaluated as a treatment for iron overload in thalassemia major. Studies in an animal model showed that prolonged treatment is associated with a decline in the effectiveness of deferiprone and exacerbation of hepatic fibrosis. ⋯ Deferiprone does not adequately control body iron burden in patients with thalassemia and may worsen hepatic fibrosis.
-
Multicenter Study
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
Women with mutations in either the BRCA1 or the BRCA2 gene have a high lifetime risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general, but it is not known whether they also protect against hereditary forms of ovarian cancer. ⋯ Oral-contraceptive use may reduce the risk of ovarian cancer in women with pathogenic mutations in the BRCA1 or BRCA2 gene.